Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma

Conclusions
Palbociclib shows encouraging results in preclinical models of HCC and represents a novel therapeutic strategy for HCC treatment, alone or particularly in combination with sorafenib. Palbociclib could potentially benefit patients with RB1-proficient tumours, which account for 70% of all patients with HCC.

Source: Gut - June 6, 2017 Category: Gastroenterology Authors: Bollard, J., Miguela, V., Ruiz de Galarreta, M., Venkatesh, A., Bian, C. B., Roberto, M. P., Tovar, V., Sia, D., Molina-Sanchez, P., Nguyen, C. B., Nakagawa, S., Llovet, J. M., Hoshida, Y., Lujambio, A. Tags: Open access Hepatology Source Type: research